ReviewCurrent fungal infection reports2021
Molecular Diagnosis of Yeast Infections.
Review in Current fungal infection reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Detection of Polysaccharide Markers of Fungal Infections by Surface-Enhanced Raman Scattering and Machine Learning Methods.Biosensors · 2026Article
- Avian Candidiasis: A Comprehensive Review of Pathogenesis, Diagnosis, and Control.Veterinary sciences · 2026Review
- Review
- The Molecular Diagnosis of Invasive Fungal Diseases with a Focus on PCR.Diagnostics (Basel, Switzerland) · 2025Review
- Invasive Candidiasis Coinfection in Patients with Severe COVID-19 Disease: Scoping Review.Pathogens (Basel, Switzerland) · 2025Article
- Global Epidemiology of Invasive Infections by UncommonJournal of fungi (Basel, Switzerland) · 2024Review
- Molecular Diagnostics for Invasive Fungal Diseases: Current and Future Approaches.Journal of fungi (Basel, Switzerland) · 2024Review
- The laboratory investigation, management, and infection prevention and control ofJournal of medical microbiology · 2024Review
- Antifungal resistance: why are we losing this battle?Future microbiology · 2024Review
- The SSS revolution in fungal diagnostics: speed, simplicity and sensitivity.British medical bulletin · 2023Article
- Performance of a Real-Time PCR Assay for the Detection of FiveJournal of fungi (Basel, Switzerland) · 2023Article
- An Evaluation of the OLMJournal of fungi (Basel, Switzerland) · 2022Article
- The Diagnosis and Treatment of Fungal Endophthalmitis: An Update.Diagnostics (Basel, Switzerland) · 2022Review
- Novel Chromogenic Medium CHROMagarJournal of fungi (Basel, Switzerland) · 2022Article
- Diagnosis of invasive fungal disease in coronavirus disease 2019: approaches and pitfalls.Current opinion in infectious diseases · 2021Review
- An update on current and novel molecular diagnostics for the diagnosis of invasive fungal infections.Expert review of molecular diagnosticsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe use of molecular tests to aid the diagnosis of invasive yeast infection, in particular invasive candidosis, has been described for over two decades, yet widespread application is limited, and diagnosis remains heavily dependent on classical microbiology. This article will review developments from the past decade in attempt to build on existing knowledge. It will highlight clinical performance and limitations while reviewing developments on recognized procedures; it will also provide insight into novel approaches incorporated in response to clinical demand (e.g. RECENT
findingsLimited methodological standardization and, until recently, unavailability of commercial options have hindered the integration of molecular diagnostics for yeasts. The development of certain, novel commercial methods has received considerable evaluation allowing a greater understanding of individual assay performance, but widespread multicentre evaluation of most commercial kits is lacking. The detection of emerging pathogens (e.g. SUMMARY: Despite over two decades of use, the incorporation of molecular methods to enhance the diagnosis of yeast infections remains limited to certain specialist centres. While the development of commercial tests will provide stimulus for broader application, further validation and reduced costs are required. Over the same period of time,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.